Edition:
United States

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

6.94USD
25 Jun 2018
Change (% chg)

$-0.09 (-1.28%)
Prev Close
$7.03
Open
$7.07
Day's High
$7.10
Day's Low
$6.94
Volume
30,765
Avg. Vol
282,677
52-wk High
$7.30
52-wk Low
$2.10

Chart for

About

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to... (more)

Overall

Beta: 1.76
Market Cap(Mil.): $917.73
Shares Outstanding(Mil.): 130.54
Dividend: --
Yield (%): --

Financials

  CERS.OQ Industry Sector
P/E (TTM): -- 41.65 34.14
EPS (TTM): -0.50 -- --
ROI: -62.34 14.42 13.10
ROE: -87.93 17.62 15.09

BRIEF-Cerus Corp Reports Q1 Loss Per Share $0.11

* Q1 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S

May 08 2018

BRIEF-Cerus Announces Health Canada Approval Of The Intercept Blood System For Platelets

* CERUS ANNOUNCES HEALTH CANADA APPROVAL OF THE INTERCEPT BLOOD SYSTEM FOR PLATELETS Source text for Eikon: Further company coverage:

Apr 25 2018

BRIEF-Cerus’ Redes Phase 3 Red Blood Cell Study Expands Into The Continental U.S.

* ’ REDES PHASE 3 RED BLOOD CELL STUDY EXPANDS INTO THE CONTINENTAL U.S.

Apr 02 2018

BRIEF-Cerus Announces The Fourth Biologics License Application Approval For A U.S. Blood Center Customer

* CERUS ANNOUNCES THE FOURTH BIOLOGICS LICENSE APPLICATION (BLA) APPROVAL FOR A U.S. BLOOD CENTER CUSTOMER

Mar 13 2018

BRIEF-Cerus Corp Reports Q4 Loss Per Share $0.10

* ORATION REPORTS RECORD FOURTH QUARTER AND YEAR END 2017 RESULTS

Mar 08 2018

BRIEF-Cerus Announces Pricing Of Public Offering Of Common Stock

* CERUS CORP - ‍PRICING OF PUBLIC OFFERING OF ITS COMMON STOCK FOR PROCEEDS OF $50.0 MILLION, BEFORE DEDUCTING ESTIMATED OFFERING EXPENSES PAYABLE BY CERUS​ Source text for Eikon: Further company coverage:

Jan 31 2018

BRIEF-Cerus Announces Public Offering Of Common Stock

* CERUS CORP - COMMENCED A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $50.0 MILLION OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

Jan 30 2018

BRIEF-Cerus - Chronic Anemia Phase 3 Study Met Primary Efficacy And Safety Endpoints

* CERUS REPORTS POSITIVE TOP-LINE RESULTS FROM CHRONIC ANEMIA PHASE 3 STUDY EVALUATING INTERCEPT RED BLOOD CELLS IN THALASSEMIA PATIENTS

Jan 23 2018

BRIEF-Cerus Corp Expects Full Year 2017 Product Revenue To Be $43.6 Million

* CERUS CORP - CERUS' UNAUDITED PRELIMINARY PRODUCT REVENUE FOR Q4 OF 2017 WAS $16.2 MILLION

Jan 08 2018

Competitors

  Price Chg
Terumo Corp (4543.T) ¥6,560 -120.00
Grifols SA (GRLS.MC) €27.00 +0.14
Grifols SA (GRLSbn.MC) €19.56 0.00

Earnings vs. Estimates